Gary Phillips is no longer serving in their board position at Zyla Life Sciences
May 30, 2020
Board and Executive Moves
Former Executive Chairman at Envisia Therapeutics, Inc.
In The News
OrphoMed's ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients; -- Topline data anticipated second half of 2021--
Apr 14, 2021 - Business Wire
OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients; --Analysis triggered after meeting enrollment milestone of 200 patients--; --Topline data anticipated second half of 2021--
Jan 26, 2021 - Business Wire
May 30, 2020 - RelSci
Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.
In The News
Mar 11, 2021 - GlobeNewswire
Global Gynecology Partnering Report 2020: Access Deals Signed Between the World's Leading Pharmaceutical and Biotechnology Companies Since 2010
Dec 23, 2020 - PR Newswire